Results 101 to 110 of about 32,499 (205)

Lopinavir concentrations of individual patients during the study period.

, 2013
The circles indicate lopinavir concentrations measured while patients were receiving tuberculosis treatment, while the squares indicate lopinavir concentrations once tuberculosis treatment has been completed.
Funeka Bango (330064), Helen McIlleron (330065), Concepta Merry (297219), Gary Maartens (60752), Peter Smith (239008), Eric H. Decloedt (330063)   +5 more
core   +1 more source

Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19

Microorganisms
The spread of COVID-19 has significantly increased research on antiviral drugs and measures such as case isolation and contact tracing. This study compared the effects of lopinavir/ritonavir and remdesivir on COVID-19 patients with a control group ...
Choon-Mee Kim, Jae Keun Chung, Sadia Tamanna, Mi-Seon Bang, Misbah Tariq, You Mi Lee, Jun-Won Seo, Da Young Kim, Na Ra Yun, Jinjong Seo, Yuri Kim, Min Ji Kim, Dong-Min Kim, Nam-Hyuk Cho   +13 more
doaj   +1 more source

Lopinavir: the old champion

, 2011
Lopinavir/ritonavir approval for use in antiretroviral treatment 10 years ago was very important for the recognition of boosted protease inhibitor (PI)-based therapy as an attractive option for first-line therapy.
Estevão Portela Nunes, Marilia Santini de Oliveira, Beatriz Grinsztejn, Santini-Oliveira, Marília, Grinsztejn, Beatriz, Nunes, Estevão Portela   +5 more
core   +1 more source

Lopinavir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV

Антибиотики и Химиотерапия, 2020
Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory.
V. N. Shchukina, S. Ya. Loginova, S. V. Borisevich, V. P. Bondarev   +3 more
doaj  

Lopinavir/Ritonavir: A Review for 2011

, 2011
Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV).
Mark Goodman, Robyn Teply, Christopher J. Destache   +2 more
core   +1 more source

Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.

, 2012
Item does not contain fulltextWe assessed pharmacokinetic (PK) parameters of reduced dose lopinavir/ritonavir (LPV/r) and compared generic and branded tablets. Twenty HIV-infected patients using protease inhibitors with HIV RNA
Burger, David M., Gorowara, Meena, Avihingsanon, A., Lange, J.M.A., Ananworanich, J., Chuleeporn Khongpetch, Burger, D.M., Praphan Phanuphak, Joep M. A. Lange, Jiratchaya Wongsabut, van der Lugt, Jasper, Wongsabut, J., Gorowara, M., Reshmie A. Ramautarsing, Lugt, J. van der, Phanuphak, P., Avihingsanon, Anchalee, Ruxrungtham, Kiat, Lange, Joep M. A., Kiat Ruxrungtham, Ramautarsing, R.A., Wongsabut, Jiratchaya, Anchalee Avihingsanon, Phanuphak, Praphan, Ramautarsing, Reshmie A., Jintanat Ananworanich, David M. Burger, Ananworanich, Jintanat, Meena Gorowara, Ruxrungtham, K., Khongpetch, C., Jasper van der Lugt, Khongpetch, Chuleeporn   +32 more
core   +1 more source

CircRNA regulates the liquid-liquid phase separation of ATG4B, a novel strategy to inhibit cancer metastasis?

Cell Stress
Anoikis is a common programmed death for most of detached cells, but cancer cells can obtain anoikis resistance to facilitate their distant metastasis through the circulation system.
Ziyuan Guo, Yang Chen, Yaran Wu, Jiqin Lian   +3 more
doaj   +1 more source

Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children

, 2012
Background The preferred antiretroviral regimen for young children previously exposed to non-nucleoside reverse transcriptase inhibitors is lopinavir/ ritonavir plus two nucleoside reverse transcriptase inhibitors.
Simonsson, Ulrika S. H.,, Yuan Ren, McIlleron, Helen, Jan-Stefan van der Walt, Mats O Karlsson, Ren, Yuan, Paolo Denti, Karlsson, Mats O,, Denti, Paolo, Chao Zhang, Helen McIlleron, Zhang, Chao, Ulrika SH Simonsson, van der Walt, Jan-Stefan,   +13 more
core   +1 more source

Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy

, 2012
Objectives: To evaluate the pharmacokinetic profile of ritonavir-boosted lopinavir in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Matteelli A., Carvalho A. C. C., Marcantoni C., Calabresi A., Dal zoppo S., Villani P., Apostoli A., Regazzi M., El-Hamad I., Bigoni S., Cusato M.   +10 more
core   +1 more source